With an exponential rise in the availability of CBD products and public opinion towards it becoming more positive over the past decade, the consumption of the ingredient has exploded. Global Market Insights, Inc., forecasts that global cannabidiol market size will be worth more than $89bn by 2026.

However, the industry will need to overcome the complex regulatory landscape as well as quality and supply challenges in the near future.

Over the past few years, cannabidiol, or CBD, has caught the publics imagination as an ingredient presenting a range of health benefits when infused in various consumables. More and more individuals worldwide are now vouching for its effectiveness in terms of alleviating certain chronic illnesses and treating several health conditions.

CBD has conquered industry after industry, from pharmaceuticals to personal care and cosmetics, food and beverages, and nutraceuticals.

Cannabidiol is the legal and non-psychoactive counterpart of tetrahydro cannabidiol (THC), the chemical compound responsible for cannabiss psychological effects. CBD is the second most-commonly used active ingredients of cannabis. The cannabinoid is derived directly from the hemp plant, a cousin of the cannabis plant, and forms an essential component of medical cannabis.

Factors such as population growth, nationalised healthcare, GDP, and cultural historic use of CBD in many European countries make the continent an attractive market for global producers of both medical and retail cannabis-based products. Hemp cultivation in the region has witnessed a massive upsurge in recent years; the European Union (EU) constitutes more than 25% of the global hemp production.

In July last year Epidiolex CBD oil received a positive recommendation for marketing approval from the European Medicines Agency (EMA) for the treatment of seizures. EMAs Human Medicines Committee (CHMP) approved the oral solution for use with clobazam for the treatment of seizures associated with Dravet syndrome or Lennox-Gastaut syndrome in patients aged two or more.

The European Commission granted marketing approval to Epidyolex, the trade name for Epidiolex in Europe, in September 2019. Epidiolex is the only federally-approved CBD product in the U.S.

Additionally, the use of CBD in cosmetics is harmonised within the European Cosmetic Regulation 1223/2009. The regulation prohibits the use of cannabis and its derivatives in cosmetic products. Essentially, EU prohibits the use of CBD derived naturally from cannabis plants. However, the use of hemp-derived or synthetically-produced cannabidiol is approved.

Europe CBD market is poised to witness monumental growth in the forthcoming years on account of surging consumer demand for safe-strength CBD products that are easily available in their normal retail environments and cultivated, extracted, processed and labelled as per the European standards.

Europe has witnessed a growing occurrence of various neurological conditions in recent years. These include epilepsy, migraine, stress, anxiety, and numerous sleeping disorders. An expanding geriatric population base indicates rising incidences of these conditions. Citing data from the European Brain Council, more than 220 million people in Europe suffer from at least one neurological condition, which is more than the populations of France, Germany, and the Great Britain combined.

Described below are some of the most prevalent neurological conditions in Europe and the effectiveness of CBD in their treatment.

Surging popularity of cannabidiol among boomers along with ongoing research and development into its potential health benefits will augment CBD market forecast. More and more boomers are adding CBD to their health regimes to help reduce stress and anxiety, get better sleep, and alleviate chronic pain. Increasing awareness towards the safety and efficacy of cannabidiol products will drive future CBD industry trends.

Hrishikesh KadamGuest ContributionGlobal Market Insightswww.gminsights.com

Do you want the latest news and updates from Medical Cannabis Network? Click here to subscribe to all the latest updates, and stay connected with us here.

See the rest here:
CBD consumption to rise across the treatment of neurological conditions - Health Europa